The cell surface antigen CD90 has recently been established as a promising marker 
such as chronic infection with hepatitis B virus or hepatitis C virus, alcoholic liver diseases and metabolic deregulation conditions such as hemochromatosis. 3 Curative therapies such as liver transplantation and resection are only effective for early-stage tumours, but not for patients with more advanced stages. 1 Progress in liver cancer biology has revealed the involvement of various somatic genetic alterations responsible for cell transformation and liver cancer progression, and the great complexity of molecular mechanisms underlying its subtyping, diagnosis, resistance and recurrence, underscoring the pressing need for further investigation.
The discovery of cancer stem cells (CSCs) over the last decade has created great interest among the research community because of their potential associations with cancer initiation and progression, and also potentially with chemotherapy resistance, prognosis and recurrence. 4 Stem cells in malignant tissues might provide a new impetus for cancer biology basic research, effective diagnosis and treatment strategies. Liver cancer stem cells, also termed hepatic CSCs, were detected as a cell population that was stained with the DNA-binding dye Hoechst 33342, thus demonstrating representative cancer cell properties. 5 Subsequently, numerous cell surface proteins, such as CD90, CD133 and CD44, were established as reliable biomarkers for liver cancer stem cells. 6 CD90, also known as Thy-1, is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein that is expressed in a number of cell types such as leucocytes, neurons, endothelial cells, fibroblasts and T cells. 7 Functional investigations have shown that CD90 is a critical regulator of pleiotropic cellular events, including cell migration and death, cell-cell interactions, tumour growth, modulation of T cell activity and neurite outgrowth, thus demonstrating a close association with multiple physiological and pathological processes, including tumorigenesis, metastasis, nerve regeneration, fibrosis and inflammation. 7 Previously, it has been shown that CD90 is expressed in hepatic stem/progenitor cells (HSPCs) and bone marrow mesenchymal stem cells, 8, 9 including primarily cultured CD133+ glioblastoma stem cells, 10 murine breast cancer stem cells 11 and hepatic cancer stem cells. 6 The CD90+ stem cells from all liver cancer tissue specimens display a strong tumorigenic capacity after being transplanted into immunodeficient mice and thus have been established as a new potential marker for liver cancer disease surveillance. 6 By comparing the gene expressional profiles between normal and tumor CD90+ cells, the expression of more than 500 genes was found to be regulated by CD90 in hepatic progenitors, including a large group of genes that are implicated in inflammation, drug resistance and lipid metabolism. 12 However, the molecular pathways responsible for the CD90-mediated tumorigenic capacity of liver cancer cells are still poorly understood.
The Sonic Hegdehog/glioma-associated oncogene 1 (SHH/GL1) pathway is involved in pattern formation regulation during early embryonic development, stem cell proliferation in the late developmental phase and in cancer stem cells. 13 The SHH/GLI-related regulatory mechanisms have been shown to be important for the maintenance of cell homeostasis during postnatal development and adult tissue growth, as well as tumorigenesis, at least partially through cancer stem cell regulation mediated by autophagy-related processes. 13 Previous reports have demonstrated that the SHH/Gli pathway is involved in liver cancer development and is responsible for HCC cell growth and dedifferentiation. 14 For quantitative analysis of cell percentages, at least 3 biological replicates were assessed.
| Magnetic-activated cell sorting (MACS)
The CD90+ liver cancer stem cells were separated using CD90
MicroBeads (order no. 130-096-253; Miltenyi Biotec) according to the manufacturer's instructions. 16 Briefly, cultured liver cancer cells were washed with PBS buffer, digested with trypsin and labelled with CD90 MicroBeads at 4°C for 40 minutes in PBS buffer supplied with 2% bovine serum albumin and 10 mmol/L ethylenediaminetetraacetic acid. After 3 washes, cell sorting was performed using a MiniMACS column. CD90+ and CD90À liver cancer cells were separately collected and counted using a cell counter under microscopy.
| Western blotting
The relative protein levels were analysed in this study by Western blotting using specific primary antibodies. Liver cancer cells were (#ab97959) were purchased from the Abcam company. At least 3 independent biological repeats were performed for quantitation of protein abundances, and GAPDH was applied as the internal standard.
| Immunohistochemistry
The protein levels of CD90, Gli1 and Gli3 in liver cancer tissues from 51 liver cancer patients were determined by immunohistochemistry using a standard immunohistochemistry protocol for paraffin-embedded tissue sections. Briefly, the liver cancer tissue and adjacent normal tissue sections were deparaffinized with xylene and rehydrated in a gradient of alcohol solutions. The tissue sections were then incubated with 3% H2O2 for 15 minutes, incubated with blocking buffer for 1 hours, and then incubated with anti-CD90, Gli1 or Gli3 antibody solutions for 1 hours. After 3 washes with PBS buffer, the liver tissue sections were then incubated with secondary antibody (biotinylated), streptavidin and diaminobenzidine reagent (Vector Laboratories, Canada).
| TCGA data analysis
The correlation of CD90, Gli1 and Gli3 expression levels with the overall survival of liver cancer patients was evaluated using The 
FPKM (number of Fragments Per Kilobase of exon per Million reads).
A P-value < .05 indicated a positive correlation.
| siRNA transfection
For knockdown of Gli1 and Gli3 expression in liver cancer cells, 97L cells with CD90 expression were transfected with siRNAs targeting Gli1 and Gli3 genes as previously described. 18 Briefly, 97L liver can- | 3681 formation capacity, 18 migration rate during the transwell assay 19 and in vivo tumorgenecity using non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice 20 of liver cancer stem cells were analysed as previously described.
| Statistical analysis
Statistical analysis in this study was performed using the SPSS software package (version 18.0, SPSS). Student's t test was carried out to evaluate the significance of differences among data from at least 3 biological repeats. A P value < .05 or <.01 was used to define a significant or extremely significant difference, respectively.
3 | RESULTS Figure 2B ). We then re-assessed the expression levels of Gli1 and Gli3 among these cancer tissues with high CD90 expression and observed elevated Gli1 and Gli3 expression in high-CD90 liver cancer tissues (Figure 2C) . The correlation of CD90 expression with Gli1 (R = .1442, P = .3128) and Gli3 (R = .2786, P = .0477) was also validated by these expression results in clinical liver cancer tissues.
3.3 | Association of CD90, Gli1 and Gli3 with survival and malignancy in liver cancer patients
For a more reliable correlation of CD90, Gli1 and Gli3 expression levels with liver cancer progression, pathological data from the Cancer Genome Atlas (TCGA) containing expression profiles of 365 liver cancer patients were further analysed as described in the Material and Methods section. We then assessed the expression levels of CD90, Gli1 and Gli3 among these cancer tissues and observed elevated CD90, Gli1 and Gli3 expression in liver cancer tissues (Fig- ure 3A-C). We also found that the average survival probability was higher for liver cancer patients with lower than with higher CD90 expression levels, demonstrating that high CD90 expression was correlated with a shortened overall survival in liver cancer patients (Figure 3D) . A similar correlation was also observed for both Gli1 and Gli3 gene expression in liver cancer tissues ( Figure 3E,F) , showing F I G U R E 2 CD90, Gli1 and Gli3 expression in liver cancer tissues. A, CD90, Gli1, and Gli3 mRNA levels in liver tissues from 51 liver cancer patients by quantitative RT-PCR. B, CD90, Gli1 and Gli3 proteins in liver cancer tissue by immunohistochemistry. C, The correlation of CD90 expression with Gli1 and Gli3 was validated in clinical liver cancer tissues. . . GAPDH was used as the internal standard. Gli1: Glioma-associated oncogene 1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase. * indicates significant differences that the expression of these 3 genes was associated with a poor prognosis of liver cancer patients. Additionally, the positive correlation of CD90 expression with Gli1 (R = .5347, P < .0001) and Gli3 (R = .4529, P < .0001) was also validated by these expression results in liver cancer tissues ( Figure 3G ,H). Consistent with the abovedescribed expression results, CD90, Gli1 and Gli3 expression levels were correlated in liver cancer tissues.
| Gli1 and Gli3 depletion depresses stem cell properties of CD90+ liver cancer cells
To analyse the role of Gli1 and Gli3 in the function of CD90+ liver cancer cells, knockdown of Gli1 and Gli3 expression was carried out using specific siRNAs in CD90+ 97L liver cancer cells. After siRNA transfection, the expression of Gli1 and Gli3 showed a significant decrease compared with the negative control ( Figure 4A,B) , demonstrating the efficient knockout of gene expression in liver cancer cells. The MTS assay showed that the proliferation rates of CD90+ liver cancer cells transfected with Gli1 or Gli3 siRNA were significantly decreased in comparison with the negative control (Figure 4C) . Similarly, the transwell assay showed that the migration rates of CD90+ liver cancer cells were remarkably suppressed by transfection with Gli1 and Gli3 siRNAs ( Figure 4D) . Moreover, the sphere formation capacity of CD90+ liver cancer stem cells was also greatly inhibited by depletion of Gli1 and Gli3 expression As (Figure 4E ). More importantly, the in vivo tumorigenicity assay showed that the sizes and weights of tumours originating from CD90+ liver cancer cells with suppressed Gli1 or Gli3 expression were markedly Specifically, the proliferation rate was markedly higher in liver cancer cells treated with SHH than the control ( Figure 5C ); the sphere formation ( Figure 5D ) and migration capacity ( Figure 5E ) of CD90+ liver cancer cells were significantly enhanced by SHH treatment; and the expression of CD90 and SOX2 genes was remarkably increased by SHH treatment in liver cancer cells expressing CD90 ( Figure 5A ,B
and Figure S2 ). After siCD90 transfection with 97L and then following SHH treatment, the proliferation rates ( Figure 5F ), sphere formation capacity ( Figure 5G ) and migration rates ( Figure 5H ) were inhibited by siCD90 treatment.
In combination with the suppressed stem cell properties of CD90+ liver cancer cells transfected with Gli siRNAs (Figure 4 ), 
| DISCUSSION
As the characterization of stem cells in various solid tumours, no effort has been spared by the research community to investigate reliable and specific cancer stem cell markers. 4, 21 In liver cancer, the identification of CD133+ cells in hepatocarcinoma cell lines has provided a good acteristics, which finally contributes to poor outcomes in patients with various human cancer types. [28] [29] [30] [31] In liver cancer, application of the JAK2 signal inhibitor has been shown to enhance adriamycininduced liver cancer cell ageing, demonstrating the association of the IL6/JAK2/STAT3 signalling pathway with liver cancer pathology. 31 More importantly, the IL6/JAK2/STAT3 signalling pathway is regulated by GLI1, which maintains STAT3 activation by binding to and activating the IL-6 gene promoter. 32 Our discovery of the regulation of IL6/JAK2/STAT3 signalling by the SHH/GLI axis in CD90+ liver cancer cells further broadened our views concerning how CD90 functions in stem cells responsible for liver cancer progression. Furthermore, the IL6/JAK2/STAT3 pathways was also found to be associated with cancer stem cell functions mediated by other stem cell biomarkers, such as CD44, 28 CD24 33 and EpCAM. 34 The prevalent functions of IL6/JAK2/STAT3 pathways in multiple stem cell marker-related processes suggested that this pathway might act as an interacting hub for integrating various stem cell signalling components during cancer stem cell growth and renewal, which merits further investigation.
| CONCLUSION
In summary, we reported herein the highly correlated expression between the cell surface biomarker CD90 and SHH-related signalling components Gli1 and Gli3 in liver cancer cells and tissues, as well as the mediating roles of SHH/Gli signalling in the regulation of CD90+ liver cancer stem cell function. We also further verified that IL6/JAK2/ STAT3 signalling functions downstream of the SHH/Gli pathway in liver cancer stem cells. These findings provided new information about the molecular signalling networks underlying CD90-mediated stem cell maintenance during liver cancer progression.
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